Key result
Novel pharmacological therapies, including ivabradine, ARNI, and SGLT2 inhibitors, have demonstrated significant efficacy in the management and prevention of chronic heart failure across multiple recent clinical trials.
Why the study?
Standard chronic heart failure pharmacotherapy in Japan relies mainly on classical agents, with few new drugs introduced due to the syndrome's diverse etiologies, though recent developments have emerged.
This review discusses the recent developments and challenges in the pharmacological treatment of chronic heart failure in Japan.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2020) conducted a review in Chronic Heart Failure. Novel pharmacological therapies (Ivabradine, ARNI, SGLT2 inhibitors) was evaluated. Novel pharmacological therapies, including ivabradine, ARNI, and SGLT2 inhibitors, have demonstrated significant efficacy in the management and prevention of chronic heart failure across multiple recent clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: